Biopharma Credit Plc Stock Net Income
| BOPCFDelisted Stock | USD 0.92 0.00 0.00% |
Fundamental analysis of BioPharma Credit allows traders to better anticipate movements in BioPharma Credit's stock price by examining its financial health and performance throughout various phases of its business cycle.
BioPharma |
BioPharma Credit PLC Company Net Income Analysis
BioPharma Credit's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current BioPharma Credit Net Income | 84.96 M |
Most of BioPharma Credit's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioPharma Credit PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, BioPharma Credit PLC reported net income of 84.96 M. This is much higher than that of the sector and significantly higher than that of the Net Income industry. The net income for all United States stocks is notably lower than that of the firm.
BioPharma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioPharma Credit's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioPharma Credit could also be used in its relative valuation, which is a method of valuing BioPharma Credit by comparing valuation metrics of similar companies.BioPharma Credit is currently under evaluation in net income category among its peers.
BioPharma Fundamentals
| Return On Equity | 0.079 | |||
| Return On Asset | 0.0493 | |||
| Profit Margin | 0.85 % | |||
| Operating Margin | 0.85 % | |||
| Current Valuation | 1.22 B | |||
| Shares Outstanding | 914.25 M | |||
| Shares Owned By Insiders | 7.68 % | |||
| Shares Owned By Institutions | 39.25 % | |||
| Price To Earning | 13.38 X | |||
| Price To Sales | 10.63 X | |||
| Revenue | 127.83 M | |||
| Gross Profit | 103.88 M | |||
| Net Income | 84.96 M | |||
| Cash And Equivalents | 10.44 M | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 14.07 X | |||
| Book Value Per Share | 1.01 X | |||
| Cash Flow From Operations | 96.44 M | |||
| Earnings Per Share | 0.06 X | |||
| Beta | 0.23 | |||
| Market Capitalization | 1.36 B | |||
| Last Dividend Paid | 0.07 |
About BioPharma Credit Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioPharma Credit PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioPharma Credit using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioPharma Credit PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in BioPharma Pink Sheet
If you are still planning to invest in BioPharma Credit PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPharma Credit's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |